Evotec SE (ETR:EVT)
6.19
+0.36 (6.18%)
At close: Feb 13, 2026
Evotec SE Employees
Evotec SE had 4,788 employees as of September 30, 2025. The number of employees decreased by 219 or -4.37% compared to the same quarter last year.
Employees
4,788
Change
-219
Growth
-4.37%
Revenue / Employee
€157,963
Profits / Employee
€33,204
Market Cap
1.10B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 4,788 | -219 | -4.37% |
| Jun 30, 2025 | 4,759 | -263 | -5.24% |
| Mar 31, 2025 | 4,766 | -289 | -5.72% |
| Dec 31, 2024 | 4,740 | -321 | -6.34% |
| Sep 30, 2024 | 5,007 | -79 | -1.55% |
| Jun 30, 2024 | 5,022 | -45 | -0.89% |
| Mar 31, 2024 | 5,055 | 103 | 2.08% |
| Dec 31, 2023 | 5,061 | 109 | 2.20% |
| Sep 30, 2023 | 5,086 | 371 | 7.87% |
| Jun 30, 2023 | 5,067 | 546 | 12.08% |
| Dec 31, 2022 | 4,952 | 754 | 17.96% |
| Sep 30, 2022 | 4,715 | 634 | 15.54% |
| Jun 30, 2022 | 4,521 | 607 | 15.51% |
| Mar 31, 2022 | 4,354 | 619 | 16.57% |
| Dec 31, 2021 | 4,198 | 626 | 17.53% |
| Sep 30, 2021 | 4,081 | 637 | 18.50% |
| Jun 30, 2021 | 3,914 | 636 | 19.40% |
| Mar 31, 2021 | 3,735 | 705 | 23.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 177,356 |
| Bayer Aktiengesellschaft | 88,502 |
| Siemens Healthineers AG | 73,840 |
| Merck KGaA | 62,346 |
| RHÖN-KLINIKUM Aktiengesellschaft | 19,041 |
| Gerresheimer AG | 13,535 |
| Carl Zeiss Meditec AG | 5,784 |
| SCHOTT Pharma AG & Co. KGaA | 4,811 |
Evotec SE News
- 16 days ago - EQS-DD: Evotec SE: Dr. Cord Dohrmann, Disposal of 3653 shares (Sell-to-cover) - Wallstreet:Online
- 16 days ago - EQS-DD: Evotec SE: Dr. Cord Dohrmann, Acquisition of 6760 shares due to vesting (Share Performance Plan 2017) - Wallstreet:Online
- 16 days ago - EQS-NVR: Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 5 weeks ago - Evotec SE (EVO) Secures Gates Foundation Grant for Biotherapeutics - GuruFocus
- 5 weeks ago - Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access - Accesswire
- 5 weeks ago - Evotec Secures Grant to Use AI for Cost-Effective Monoclonal Antibody Development - Wallstreet:Online
- 5 weeks ago - EQS-News: Just – Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access - Wallstreet:Online
- 6 weeks ago - Evotec SE: Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations - Finanz Nachrichten